Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Possibly Marketed Outside US

1

US Previously Marketed

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Aldose reductase

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Not Provided

1

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1921

1

2020

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Cataract

1

Gingivitis

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Preventing

1

Primary

1

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

1

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Caspar Neumann

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

2

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

2

CFR

2

CHEBI

2

DAILYMED

2

ECHA (EC/EINECS)

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 2 of 2 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

Thymol

3J50XA376E

Export Data
Search for Structure

Status:

US Previously Marketed

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Aldose reductase

Conditions:

Thymol, a monoterpene, obtained from thyme oil or other volatile oils, is used as a stabilizer in pharmaceutic preparations. It has been used for its antiseptic, antibacterial, and antifungal actions to help reduce and prevent plaque and gingivitis. ...

Recently was shown, that this substance was able to significantly reduce the oxidative stress associated with cataract. The results suggested that thymol might be a potential therapeutic approach in the prevention of diabetic complications through its aldose reductase enzyme inhibitory and antioxidant activities.

P-CYMENE

1G1C8T1N7Q

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 2020

Class (Stereo):

CHEMICAL (ACHIRAL)

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1